Unity Biotechnology CEO Anirvan Ghosh sells shares worth $1,431

Published 05/02/2025, 22:34
Unity Biotechnology CEO Anirvan Ghosh sells shares worth $1,431

Anirvan Ghosh, the Chief Executive Officer of Unity Biotechnology, Inc. (NASDAQ:UBX), recently sold 642 shares of the company’s common stock. The biotech company, currently valued at $38.42 million, has seen its stock surge over 65% in the past six months. The transaction, which took place on February 4, 2025, was executed at a price of $2.23 per share, amounting to a total value of $1,431. This sale was made pursuant to a Rule 10b5-1 trading plan to cover tax obligations related to the vesting of Restricted Stock Units. According to InvestingPro analysis, the stock is currently trading near its Fair Value, with a current price of $2.30. Following the transaction, Ghosh holds 75,251 shares of Unity Biotechnology. While the company maintains a healthy current ratio of 3.45, InvestingPro data reveals that UBX is quickly burning through cash, with eight additional key insights available to subscribers.

In other recent news, Unity Biotechnology has been the focus of several significant developments. Chardan Capital Markets initiated coverage of Unity Biotechnology with a Buy rating, emphasizing the potential of the company’s lead senolytic candidate, UBX1325, in the treatment of diabetic macular edema (DME). The firm’s analysts highlighted UBX1325’s unique mechanism that could restore diseased retinal tissue, potentially offering a new treatment option for DME patients.

In addition, Unity Biotechnology announced the appointment of Federico Grossi, M.D., Ph.D., as its new chief medical officer. Dr. Grossi’s extensive background in clinical development and regulatory strategy, particularly in ophthalmology, is expected to be a strategic addition to Unity’s executive leadership team. His leadership is anticipated to accelerate the development of Unity’s therapeutic portfolio.

Lastly, Piper Sandler, a leading investment bank, outlined several companies with key Phase 2b readouts expected in 2025, and Unity Biotechnology was among the firms mentioned. These developments suggest that Unity Biotechnology is making significant strides in its endeavors, particularly with its UBX1325 candidate and new leadership.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.